Real world escalated Beacopdac delivers similar outcomes to escalated Beacopp and superior outcomes to response-adapted (RATHL) ABVD, while potentially reducing toxicity compared with escalated Beacopp
Authors
Santarsieri, A.Sturgess, K.
Brice, P.
Menne, T. F.
Osborne, W.
Creasey, T.
Ardeshna, K. M.
Behan, S.
Bhuller, K.
Booth, S.
Collins, G. P.
Cwynarski, K.
Davies, A.
Furtado, M.
Gallop-Evans, E.
Hodson, A.
Iyengar, S.
Jones, S. G.
Linton, Kim M
Martinez-Calle, N.
McKay, P.
Nagumantry, S. K.
O'Mahony, D.
Phillips, B.
Phillips, N.
Rudge, J. F.
Shah, N.
Stafford, G.
Sternberg, A.
Trickey, R.
Uttenthal, B. J.
Wetherall, N.
McMillan, A. K.
Follows, G. A.
Affiliation
Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, CambridgeIssue Date
2021
Metadata
Show full item recordCitation
Santarsieri A, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, et al. Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398803175.Journal
BloodDOI
10.1182/blood-2021-146242Additional Links
https://dx.doi.org/10.1182/blood-2021-146242Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-146242